NYSE (USA) TSX (CANADA)

Directory of Stock Market Company

This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.

Search into NYSE and TSX
by quote, company name or key word

facebooktwitterlinkedin
Mail

AEGR - Aegerion Pharmaceuticals Inc

Aegerion Pharmaceuticals, Inc. (Aegerion), incorporated in February 2005, is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat severe lipid disorders. Its lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor (MTP-I), which limits secretion of cholesterol and triglycerides from the inte","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"

# AEGRhart

Aegerion Pharmaceuticals Inc News


Aegerion Pharmaceuticals Announces Participation at Deutsche Bank and Bank of ...
PharmaLive.com (press release) - May 4, 2012
CAMBRIDGE, Mass., May 2, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare ...

Aegerion Pharmaceuticals Announces Participation at Deutsche Bank and Bank of ...
Broadcast Newsroom - May 2, 2012
CAMBRIDGE, Mass., May 2, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare ...

Health Care Sector Wrap
Fox Business - May 1, 2012
While the S&P 500 grew 0.6%, the Health Care sector (XLV) showed little movement during trading today. BG Medicine (BGMD) declined 16.9% to close at $5.51, moving below its 50-day moving average of $6.47 and 200-day moving average of $5.84.

Aegerion Pharmaceuticals Announces First Quarter 2012 Financial Results
MarketWatch (press release) - May 1, 2012
CAMBRIDGE, Mass., May 1, 2012 (GlobeNewswire via COMTEX) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) , an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often ...

Aegerion Pharmaceuticals Announces First Quarter 2012 Financial Results
GlobeNewsWire (press release) - May 1, 2012
CAMBRIDGE, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare ...

Aegerion Pharmaceuticals Announces FDA Acceptance of New Drug Application for ...
MarketWatch (press release) - Apr 30, 2012
CAMBRIDGE, Mass., Apr 30, 2012 (GlobeNewswire via COMTEX) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) , an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often ...
Aegerion Pharma Says FDA Accepted NDA For Lomitapide For Review - Quick Facts - NASDAQ

Aegerion Pharmaceuticals Inc Announces FDA Acceptance Of New Drug Application For Review
Reuters Key Development - Apr 30, 2012

Aegerion Pharmaceuticals Inc Announces EMA Acceptance For Review Of Marketing Authorization Application For Lomitapide
Reuters Key Development - Mar 20, 2012

Aegerion Pharmaceuticals Inc Submits Marketing Applications For Lomitapide In U.S. And EU
Reuters Key Development - Mar 5, 2012

NYSE Media Coverage Selection of the best articles found in your favorit medias

Next Company >>